Table 2. Univariate DFS and OS analysis of prognostic factors in patients with cholangiocarcinoma who received AGC (n=68) and those who did not (n=59).

	AGC(+) (n=68)					AGC(−) (n=59)
		DFS		OS			DFS		OS
	N	5-Year survival (%)	P-value	5-Year survival (%)	P-value	N	5-Year survival (%)	P-value	5-Year survival (%)	P-value
Age (years)
<70	35	38	0.941	61	0.225	31	18	0.834	26	0.472
⩾70	33	36		30		28	14		15
Gender
Male	42	40	0.518	53	0.566	43	17	0.483	20	0.56
Female	26	19		35		16	13		21
Tumour location
Intrahepatic	12	20	0.129	56	0.479	8	25	0.56	13	0.841
Perihilar	36	43		49		24	17		27
Distal	20	33		39		27	13		16
Residual tumour
R0	53	42	0.077	50	0.11	42	23	0.001	29	<0.001
R1	15	16		36		17	0		0
Pathological differentiation
Well	28	54	0.003	62	0.011	27	27	0.187	34	0.049
Moderate, poor	40	20		32		32	4		7
Lymph node metastasis
Present	31	34	0.057	31	0.009	34	9	0.037	10	0.007
Absent	37	40		60		25	26		35
UICC pT factor
T1,2,2a,2b	34	43	0.216	56	0.126	31	21	0.092	27	0.167
T3,4	34	28		35		28	10		12
UICC stages
II, A, B	35	43	0.042	66	0.012	38	21	0.22	27	0.017
III, A, B, IV, A, B	33	30		25		21	8		10
hENT1 expression
High	45	45	0.005	55	0.036	41	18	0.796	24	0.913
Low	23	21		32		18	12		12
RRM1 expression
High	35	25	0.015	33	0.035	32	16	0.642	22	0.883
Low	33	47		59		27	16		19
Combined hENT1 and RRM1 classification
High hENT1/low RRM1	20	58	0.003	75	0.015	12	18	0.778	25	0.994
High hENT1/high RRM1	25	24		34		29	18		23
Low hENT1/low RRM1	13	19		32		15	13		13
Low hENT1/high RRM1	10	25		36		3	0		0
High hENT1/low RRM1	20	58	<0.001	75	0.001
The other three expression combinations	48	22		32

Abbreviations: AGC=adjuvant gemcitabine-based chemotherapy; DFS=disease-free survival; hENT1=human equilibrative nucleoside transporter 1; OS=overall survival; RRM1=ribonucleotide reductase subunit 1.

The other three expression combinations=high hENT1/high RRM1 expression or low hENT1/low RRM1 expression or low hENT1/high RRM1 expression. Values in bold represent P-values <0.05.